Avalon GloboCare Corp. (NASDAQ:ALBT) Short Interest Update

Avalon GloboCare Corp. (NASDAQ:ALBT) was the target of a significant decline in short interest during the month of January. As of January 15th, there was short interest totalling 22,400 shares, a decline of 80.4% from the December 31st total of 114,200 shares. Based on an average trading volume of 1,430,000 shares, the short-interest ratio is presently 0.0 days. Currently, 5.3% of the company’s shares are short sold.

Avalon GloboCare Trading Up 0.1 %

Avalon GloboCare stock opened at $3.39 on Thursday. Avalon GloboCare has a 12-month low of $2.11 and a 12-month high of $21.60. The firm has a 50-day moving average price of $3.44 and a 200-day moving average price of $3.83. The firm has a market capitalization of $3.69 million, a PE ratio of -0.17 and a beta of 0.19.

Avalon GloboCare (NASDAQ:ALBT) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.82) earnings per share for the quarter. The company had revenue of $0.35 million for the quarter.

Avalon GloboCare Company Profile

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.